<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073018</url>
  </required_header>
  <id_info>
    <org_study_id>METc 97/10/172</org_study_id>
    <nct_id>NCT03073018</nct_id>
  </id_info>
  <brief_title>Prevention of Renal and Vascular Endstage Disease Intervention Trial</brief_title>
  <acronym>PREVEND-IT</acronym>
  <official_title>Prevention of Renal and Vascular Endstage Disease Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Netherlands Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <brief_summary>
    <textblock>
      The Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) was
      designed to determine whether intervention with the angiotensin-converting enzyme (ACE)
      inhibitor fosinopril and/or the hydroxymethylglutaryl coenzyme A reductase inhibitor
      pravastatin reduced cardiovascular and renal events in nonhypertensive,
      nonhypercholesterolemic subjects with microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study describes the rationale, design, and baseline characteristics of a trial to
      determine whether treatment with fosinopril 20 mg/day and/or pravastatin 40 mg/ day will
      prevent cardiovascular and renal disease in nonhypertensive (RR &lt;160/100 mm Hg and not using
      antihypertensive medication) and nonhypercholesterolemic (total cholesterol &lt;8.0 or &lt;5.0
      mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men
      and women with persistent microalbuminuria (urinary albumin excretion &gt;10 mg/L once in an
      early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine
      collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
      single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial
      design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum
      of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause
      mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2)
      myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular
      accident and/or (6) end-stage renal disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of all-cause mortality, MACE and/or end-stage renal disease</measure>
    <time_frame>4 years</time_frame>
    <description>Combined incidence of all-cause mortality or hospital admission for documented (1) non-fatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence of all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of treatment on microalbuminuria</measure>
    <time_frame>4 years</time_frame>
    <description>albumin excretion mg/24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of treatment on LDL cholesterol</measure>
    <time_frame>4 years</time_frame>
    <description>in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of treatment on blood pressure</measure>
    <time_frame>4 years</time_frame>
    <description>in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hospital admission</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence of hospital admission for documented (1) non-fatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">864</enrollment>
  <condition>Microalbuminuria</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Renal Disease</condition>
  <arm_group>
    <arm_group_label>Fosinopril + Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosinopril + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosinopril (20 mg) + pravastatin placebo once daily for 4 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin (40 mg) + fosinopril placebo once daily for 4 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fosinopril placebo and pravastatin placebo once daily for 4 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosinopril</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Fosinopril + Pravastatin</arm_group_label>
    <arm_group_label>Fosinopril + Placebo</arm_group_label>
    <other_name>Monopril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Fosinopril + Pravastatin</arm_group_label>
    <arm_group_label>Pravastatin + Placebo</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosinopril Placebo</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Pravastatin + Placebo</arm_group_label>
    <arm_group_label>Double Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin Placebo</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Fosinopril + Placebo</arm_group_label>
    <arm_group_label>Double Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent microalbuminuria (urinary albumin excretion &gt;10mg/L once in an early
             morning spot urine and 15 to 300 mg/24 hours at least once in two 24-hour urine
             samples)

          -  No hypertension (RR &lt;160/100 mm Hg, no anti-hypertensive medication)

          -  No hypercholesterolemia (total cholesterol &lt;8.0 or &lt;5.0 mmol/L in case of previous
             myocardial infarction and not using lipid-lowering medication)

        Exclusion Criteria:

          -  Creatinine clearance &gt;60% of the normal age-adjusted value

          -  Serum potassium &gt;5.5 mmol/L

          -  History of chronic liver disease

          -  Lactate dehydrogenase, aspartate-amino transferase or alanine-amino transferase &gt;3
             times the upper limit of normal

          -  Use of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists

          -  Use of insulin

          -  Previously documented allergy or intolerance to study drugs

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wiek H van Gilst, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <reference>
    <citation>Diercks GF, Janssen WM, van Boven AJ, Bak AA, de Jong PE, Crijns HJ, van Gilst WH. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol. 2000 Sep 15;86(6):635-8.</citation>
    <PMID>10980214</PMID>
  </reference>
  <reference>
    <citation>Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004 Nov 2;110(18):2809-16. Epub 2004 Oct 18.</citation>
    <PMID>15492322</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. Wiek H. van Gilst</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Fosinopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

